GlobeNewswire

Casa Systems Showcases Transformational Access Technology Solutions for Broadband Networks at ANGA COM 2019

Del

Robust end-to-end portfolio opens up new opportunities for service providers including Low Latency DOCSIS 3.1, Standards-Based Virtual CCAP (vCCAP) with Orchestration, Profile Management and Multiservice Edge Access

ANDOVER, Mass., June 05, 2019 (GLOBE NEWSWIRE) -- To keep up with the growing demands of an all-connected world, service providers are looking for innovative and efficient ways to increase capacity and improve agility of broadband networks while reducing space and power constraints. Casa Systems accelerates network innovation with its suite of intelligent, end-to-end broadband solutions that provide a clear path to a converged, virtualized and distributed multi-access network. 

At this week’s ANGA COM conference, Casa Systems is demonstrating end-to-end, interoperable, standards-based solutions that allow service providers to take a step-wise approach to transform cable networks for the all-connected future.  In addition, Casa’s product and solution experts are participating in panels that discuss the benefits of multiservice 5G core, virtual CCAP, and low latency DOCSIS 3.1 best practices. 

“There are many paths that service providers can take to transform their networks. Casa Systems has the expertise and technology to help service providers navigate their broadband network’s potential no matter where they are in the process,” said Peter Wolff, VP Wireline Product Management at Casa Systems. “Our portfolio of end-to-end agile broadband solutions, from the network core to the network edge, are engineered for the performance, flexibility and scale that cable, wireless, fixed and converged networks require. At ANGA COM, we are demonstrating solutions that enable service providers to fully maximize their existing network and prepare for the converged future.” 

Casa Systems Featured Demonstrations in Hall 7, Stand #G10
                                                            
Standards-Based vCCAP with Orchestration 
Developed for the virtual compute environment from the ground up, the Axyom vCCAP is designed to support full interoperability in a distributed access architecture. Casa is demonstrating an end-to-end, standards-based, integrated and interoperable solution that features bottoms-up provisioning using our new Axyom™ Intelligent Access Manager (IAM) - powered by Intraway, a leading software provider in Americas.  The new IAM automates the Remote PHY Device (RPD) provisioning process.  IAM provides AP-based tools and work-flow modules for both legacy equipment and next-generation components that can scale during the transition to distributed access architectures.  

Multiservice Edge Access  
The latest addition to Casa’s converged software architecture that includes 5G and FTTx, the Axyom™ Virtual Broadband Network Gateway (vBNG) Router solution is the industry’s first virtualized broadband network gateway that delivers superior performance, multi-dimensional scaling, and flexibility needed to address the greater diversity of broadband demands. At ANGA COM, Casa is showcasing an end-to-end, integrated, interoperable service provider edge access solution that offloads and distributes the data plane so service providers can better control and distribute intelligence to the network edge. 

Low Latency DOCSIS 3.1  
From gaming to virtual reality to wireless backhaul, service providers are looking for solutions to keep pace with demands for more bandwidth and lower latency to support applications without choppiness, freezing or other latency issues.  Casa’s enhanced software-based architecture provides significant improvement to keep ahead of increasingly latency-sensitive application requirements.

Increase Spectral Efficiency with PMA
Service providers are looking for ways to provide unique and innovative services and solutions that consumers demand and want.  With a profile management application (PMA) solution, service providers can deliver a consistent user experience with network management solutions that dynamically adjust to changing network conditions.  The result is increased spectral efficiency which means higher throughputs and better performance. 

Visit Casa Systems and view these demos in Hall 7, Stand #G10 at ANGA COM 2019 .

About Casa Systems, Inc.
Casa Systems, Inc. (Nasdaq: CASA) delivers converged broadband technology solutions that enable mobile, cable and fixed network service providers to meet the growing demand for gigabit bandwidth and services. Our suite of distributed and virtualized solutions for fixed and mobile 5G ultra-broadband networks are engineered for performance, flexibility and scale. Commercially deployed in over 70 countries, Casa serves more than 450 Tier 1 and regional service providers worldwide.

For more information, please visit us at http://www.casa-systems.com                                                             

CONTACT INFORMATION:

Alicia Thomas                                                                      
Casa Systems, Inc.                                                               
100 Old River Road                                                               
Andover, Mass. 01810                                                           
+1.817.909.8921                                                                    
alicia.thomas@casa-systems.com                                       

 

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress15.6.2019 16:00:00 CESTPressemelding

CRESTWOOD, Ky. and WALTHAM Mass., June 15, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced updated data from its Phase 2 PLAUDIT study of APL-2 in patients with autoimmune hemolytic anemia (AIHA), including cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA). Data from the PLAUDIT trial will be presented in an oral presentation today at the 24th Annual Congress of the European Hematology Association (EHA), held in Amsterdam, the Netherlands. In the ongoing PLAUDIT study, 13 patients with CAD have been enrolled to receive subcutaneous APL-2 treatment, of which 10 patients have been on APL-2 for at least 168 days. The trial has also enrolled 11 patients with wAIHA, 8 of which were Direct Antiglobulin Test (DAT) C3+ (C3+ wAIHA); 5 of the C3+ wAIHA patients

Carpenter Technology and BMT Aerospace Combine Expertise in Redesign and Production of Additively Manufactured Aerospace Component14.6.2019 15:17:00 CESTPressemelding

LE BOURGET, France, June 14, 2019 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE:CRS) and Belgium-based BMT Aerospace today announced their cooperation in the development of an additively manufactured (AM) aerospace pinion, using Carpenter Technology’s Custom 465® Stainless. BMT Aerospace and its subsidiary BMT Additive initiated the project by partnering with Carpenter Technology to produce a redesigned pinion. The redesign project was initiated to enable the benefits of additive manufacturing using high quality, printable material that would attain the high-performance expectations for the application. “BMT Aerospace strongly believes in the disruptive potential of additive manufacturing and its possibilities in aerospace,” explained Ewald Goossens, Business Unit Manager of BMT Additive. “As a small player in the market, we strongly believe in cooperation opportunities like these, where each partner can rely and build on a project, starting from its own expertise. Our spe

Immunophotonics and Clinical Laserthermia Systems Announce Immuno-Oncology Research Collaboration and Clinical Trials for Cancer Patients with Solid Tumors14.6.2019 13:00:00 CESTPressemelding

Collaboration will Combine Immunophotonics’ Proprietary Drug, IP-001, and CLS’s TRANBERG Laser Thermal Therapy System and imILT Method ST. LOUIS and LUND, Sweden, June 14, 2019 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. and Clinical Laserthermia Systems, AB (STO:CLS B) (CLS) today announced they have entered into a research collaboration agreement to support a Phase 1b/2a clinical trial for cancer patients with certain solid tumor indications. The research will utilize each company’s respective products and methodologies during treatments and is intended to support early phase clinical trials facilitated by a leading clinical organization. Eligible patients with solid tumors will be treated using the locally administered CLS Immunostimulating Interstitial Laser Thermotherapy (imILT) method, followed immediately by an intratumoral injection of Immunophotonics’ lead asset, IP-001. Under the agreement, the CLS TRANBERG Laser and single-use products will be used in eligible patients enrolle

iCAD Introduces ProFound AI™ for 2D Mammography in Europe13.6.2019 14:00:00 CESTPressemelding

Company to showcase its newest artificial intelligence software solution, ProFound AI for 2D Mammography, in addition to ProFound AI for Digital Breast Tomosynthesis at the SIFEM Medical Conference in France NASHUA, N.H. and LILLE, France, June 13, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the launch of ProFound AI™ for 2D Mammography in Europe. This software is the latest addition to iCAD’s deep-learning, artificial intelligence platform and follows the launch of ProFound AI™ for Digital Breast Tomosynthesis (DBT), which was CE Marked in March 2018 and FDA cleared in December 2018. ProFound AI for 2D Mammography and ProFound AI for DBT will both be featured in the iCAD exhibition booth (#24) at the Société Française d'Imagerie de la FEMme (SIFEM) medical conference from June 13-15, 2019 at the Grand Palais in Lille, France. “iCAD is at the forefront of the fight ag

Telix Pharmaceuticals and Eczacıbaşı-Monrol Sign Manufacturing and Distribution Agreement13.6.2019 13:54:00 CESTPressemelding

MELBOURNE, Australia and ISTANBUL, Turkey, June 13, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR) has today announced that it has concluded a master services and distribution agreement with Eczacıbaşı-Monrol. Under the terms of the agreement, Telix has appointed Eczacıbaşı-Monrol as a radiopharmaceutical production partner and distributor in Turkey/Middle East/North Africa. Eczacıbaşı-Monrol is commercially active in more than 40 countries, including important growth territories that complement Telix’s current commercial strategy for the US and Europe. The parties will initially focus on the production and distribution of TLX250-CDx (89Zr-girentuximab) for imaging of renal cell carcinoma with Positron Emission Tomography (PET), including to support the ad

Highly Accurate Long-Read Sequencing of Human Genomes Leads to Discovery of Disease-Causing Variants13.6.2019 13:30:00 CESTPressemelding

Identification of pathogenic structural variants with SMRT Sequencing improves solve rate for rare and Mendelian diseases MENLO PARK, Calif., June 13, 2019 (GLOBE NEWSWIRE) -- While DNA sequencing tools have been useful for determining the genetic cause of many diseases, there remain a large number that are left unexplained. Recently, scientists have adopted Single Molecule, Real-Time (SMRT®) Sequencing from Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, to study previously unsolved diseases. Many high-impact research publications report expanded variant detection in human genomes, leading to discovery of disease-causing variants and genes underlying rare and Mendelian disorders. In a Nature Communications publication, scientists report that most structural variants (SVs) and large indels are undetected in today’s human genetic studies, which likely accounts for some of the missing heritabi